Mohamed Othman, MD
Gastroenterology · Houston, TXNPI 1881733871
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (35.6%), consulting fees and education — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Olympus Corporation Of The Americas at 29.0% of the total. Reporting peaked in 2019 at $247,934 and has fallen 81.0% since, to $47,111 in 2025. Among gastroenterology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 981 payments — averaging $792.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus Corporation Of The Americas$226K
- Boston Scientific$190K
- AbbVie$122K
- Creo Medical Inc.$70K
- Lumendi LLC$43K
- Conmed Corporation$28K
- plus $100K from 26 others
Across 38 payments — averaging $21,052 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$279K
- Boston Scientific$174K
- Lucid Diagnostics Inc.$162K
- Lumendi LLC$120K
- Conmed Corporation$64K
- Medtronic$600
What the payments were for
- Consulting fees$229,08429%
- Speaking & faculty fees$276,57636%
- Travel & lodging$54,0467%
- Food & beverage$21,4113%
- Education$196,36725%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus Corporation Of The Americas | 321 | $225,572 |
| Boston Scientific | 267 | $189,516 |
| AbbVie | 130 | $122,288 |
| Creo Medical Inc. | 32 | $70,003 |
| Lumendi LLC | 40 | $42,518 |
| Conmed Corporation | 36 | $27,972 |
| Olympus Corporation | 12 | $18,561 |
| Ambu A/s | 2 | $18,158 |
| Apollo Endosurgery US Inc | 16 | $11,735 |
| Olympus Latin America, Inc. | 12 | $11,273 |
| Nestle Healthcare Nutrition Inc. | 2 | $7,975 |
| Olympus America Inc. | 42 | $5,944 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $5,098 |
| Olympus Medical Systems Corporation | 3 | $3,938 |
| Johnson & Johnson(2 entities) | 6 | $3,486 |
| Aries Pharmaceuticals, Inc. | 4 | $2,965 |
| Covidien LP | 1 | $2,250 |
| Ambu Inc. | 12 | $2,228 |
| Pentax Of America, Inc. | 2 | $2,027 |
| Pinnacle Biologics, Inc | 3 | $1,229 |
| Cook Medical LLC | 4 | $566 |
| Applied Medical Resources Corporation | 5 | $547 |
| ERBE USA Inc | 3 | $410 |
| Medtronic(2 entities) | 5 | $345 |
| 3-d Matrix, Inc. | 1 | $249 |
| Micro-tech Endoscopy USA, Inc. | 4 | $246 |
| Fujifilm Healthcare Americas Corporation | 2 | $191 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $80 |
| Laborie Medical Technologies Corp. | 1 | $52 |
| Madrigal Pharmaceuticals | 1 | $23 |
| Sanofi | 1 | $20 |
| Novo Nordisk | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Olympus Hemostasis Devices$115,566
- Olympus EMR & ESD Devices$113,886
- Olympus EndoTherapy Accessories$102,038
- Olympus GI Accessories$48,433
- ORISE$42,127
- SPEEDBOAT$36,002
- DiLumen$35,389
- Single Use Electrosurgical Knife KD-655$33,832
- Creon$33,657
- Resolution 360 Clip$32,950
- Speedboat Ultraslim (SB1L)$31,183
- DISPOSABLE DISTAL ATTACHMENT$31,030
- Olympus EUS Devices$26,993
- BEAMER SYSTEM$25,627
- Single Use Repositionable Clip$24,590
- Resolution 360 ULTRA Clip$23,382
- Olympus$17,953
- Single Use Electrosurgical Hemostatic Forceps$16,814
- X-Tack Endoscopic HeliX Tacking System$15,300
- Long Clip$14,141
How this compares
$777,484 in reported general payments places this provider in the 95th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 81 | $224,475 |
| ZenpepLipase/Protease/Amylase | 22 | $99,038 |
| LinzessLinaclotide | 23 | $12,961 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 55 | $3,017 |
| Sucralfate | 20 | $481 |
| Omeprazole | 43 | $466 |
| Ondansetron Hcl | 34 | $461 |
| Fluconazole | 18 | $124 |
| Pantoprazole Sodium | 23 | $115 |
| Metoclopramide Hcl | 13 | $86 |
| Promethazine Hcl | 12 | $19 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $122,288 | $237,437104 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,350 gastroenterology providers in Texas.
Other gastroenterology in Houston
- Bincy AbrahamHouston$1.6M
- Mazen NoureddinHouston$1.5M
- Stephen PappasHouston$1.4M
- Brooks CashHouston$867K
- Isaac RaijmanHouston$565K
- Kalpesh PatelHouston$382K
- Victor Ankoma-SeyHouston$340K
- John VierlingHouston$270K
- George TriadafilopoulosHouston$192K
- Chukwuma EgwimHouston$145K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.